Impact of the Normalized Copy Number of BCR-ABL Transcript upon Diagnosis on Prognosis in CML Patients Treated with Imatinib-Mesylate

Christophe Martinaud, Aurélie Mayet, Sophie Bousquet, Nathalie Beaufils, Jean Gabert, Sophie Raynaud, Marie-Joelle Mozziconacci

.

DOI: 10.4236/ojbd.2011.12004                

Abstract

Quantification of the BCR-ABL transcript is recommended to follow-up CML patients treated by imatinib mesylate (IM). Results are expressed as a normalized copy number (NCN) of BCR-ABL. We studied a cohort of 98 CML patients under IM as a first treatment and monitored by RQ-PCR after 12, 18 and 24 months according to the European LeukemiaNet recommendations. Our results support the hypothesis of an independent correlation between BCR-ABL NCN at diagnosis and major molecular response at 18 and 24 months in an inverse relationship. We also highlighted the possibility to use the NCN at diagnosis as a warning at diagnosis, and may be useful to identify patients who could benefit of a more rigorous follow-up.

Keywords

Chronic Myeloid Leukemia, RQ-PCR, Normalized Copy Number, BCR-ABL

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	B. J. Druker, F. Guilhot, S. G. O'Brien, et al., “Five-Year Follow-Up of Patients Receiving Imatinib for Chronic Myeloid Leukemia,” New England Journal of Medicine, Vol. 355, No. 23, 2006, pp. 2408-2417. doi:10.1056/NEJMoa062867
[2]	H. Kantarjian, C. Sawyers, A. Hochhaus, et al., “Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia,” New England Journal of Medicine, Vol. 346, No. 24, 2002, pp. 645-652. doi:10.1056/NEJMoa011573
[3]	T. P. Hughes, J. Kaeda, S. Branford, et al., “Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chr- onic Myeloid Leukemia,” New England Journal of Medicine, Vol. 349, No. 15, 2003, pp. 1423-1432. doi:10.1056/NEJMoa030513
[4]	M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, et al., “Evolving Concepts in the Management of Chronic Myeloid Leukemia: Recommendations from an Expert Panel on Behalf of the European Leukemia Net,” Blood, Vol. 108, No. 6, 2006, pp. 1809-1820. doi:10.1182/blood-2006-02-005686
[5]	M. Baccarani, J. Cortes, F. Pane, et al., “Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European Leukemia Net,” Journal of Clinical Oncology, Vol. 27, 2009, pp. 6041-6051. doi:10.1200/JCO.2009.25.0779
[6]	T. Hughes, M. Deininger, A. Hochhaus, et al., “Monitoring CML Patients Responding to Treatment with Tyrosine Kinase Inhibitors: Review and Recommendations for Harmonizing Current Methodology for Detecting BCR-ABL Transcripts and Kinase Domain Mutations and for Expressing Results,” Blood, Vol. 108, No. 1, 2006, pp. 28-37. doi:10.1182/blood-2006-01-0092
[7]	D. Marin, D. Milojkovic, E. Olavarria, et al., “European Leukemia Net Criteria for Failure or Suboptimal Response Reliably Identify Patients with CML in Early Chronic Phase Treated with Imatinib Whose Eventual Outcome is Poor,” Blood, Vol. 112, 2008, pp. 4437-4444. doi:10.1182/blood-2008-06-162388
[8]	M. Baccarani, G. Rosti, A. de Vivo, et al., “A Randomized Stu- dy of Interferon-Alpha Versus Interferon-Alpha and Low- Dose Arabinosyl Cytosine in Chronic Myeloid Leukemia,” Blood, Vol. 99, No. 5, 2002, pp. 1527-1535. doi:10.1182/blood.V99.5.1527